Delivery Order 36F79725D0093-36C26026F0298
Award Date 7/1/26
Potential Completion Date 10/31/26
Potential Value $469K
Federal Agency
Ultimate Awardee
NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Bedford, MA 01730, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., was awarded a delivery order valued at $819,179.44 by Veterans Integrated Service Network 20 (VISN 20) on July 1, 2026, for the supply of PYLARIFY (piflufolastat F-18), a radioactive diagnostic imaging agent used in positron emission tomography (PET) scans for prostate cancer detection and localization. This firm fixed-price delivery order, which carries no set-aside designation, has an ultimate completion...
- Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., was awarded a delivery order valued at $332,280.71 by Veterans Integrated Service Network 20 (VISN 20) on July 5, 2022, for the supply of PYLARIFY (piflufolastat F-18), a radioactive diagnostic imaging agent used in positron emission tomography (PET) scans for prostate cancer detection. This is a firm fixed-price contract with no set-aside designation and an ultimate completion date of July 4, 2023. The...
- Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., was awarded a $599,047.52 firm fixed-price delivery order by Veterans Integrated Service Network 5 on February 1, 2026, for PYLARIFY (piflufolastat F-18) injection radiopharmaceuticals. The contract, with an ultimate completion date of March 1, 2026, contains no set-aside designation and represents performance at the company's facility in Bedford, Massachusetts. This delivery order falls under the...
- The Department of Veterans Affairs, Veterans Integrated Service Network 23 (VISN 23) awarded a delivery order to Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., for the supply of PYLARIFY imaging agent on October 1, 2024. This $570,744.66 firm fixed-price delivery order, with an ultimate completion date of August 31, 2025, represents a non-competitive procurement issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and...
- Veterans Integrated Service Network 12 issued a delivery order to Progenics Pharmaceuticals Inc. on May 1, 2025, with a ceiling value of $4,694,501.12 for supply of PYLARIFY radiopharmaceutical under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The order covers base performance plus three one-year option years. Place of performance is Bedford, MA. Ultimate completion date is April 30, 2026. Progenics Pharmaceuticals operates as a division of Lantheus Medical Imaging, Inc....
- The Department of Veterans Affairs, Veterans Integrated Service Network 12 (VISN 12) awarded a $187,653.44 firm fixed-price delivery order to Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., on February 1, 2026. The contract calls for delivery of PYLARIFY (piflufolastat F-18), a specialized radiopharmaceutical diagnostic imaging agent used in positron emission tomography (PET) scans for prostate cancer detection and localization. Performance is scheduled...
- Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., was awarded a delivery order valued at $4.64 million by Veterans Integrated Service Network 22 on November 1, 2024, for the supply of PYLARIFY (piflufolastat F-18) radiopharmaceutical products. PYLARIFY is a positron emission tomography imaging agent used for the detection and localization of prostate cancer in diagnostic procedures. This firm fixed-price delivery order, which carries no set-aside...
- Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., was awarded a $484,351.04 delivery order on February 1, 2025, by Veterans Integrated Service Network 12 for the supply of PYLARIFY Injection (piflufolastat F-18), a radioactive diagnostic imaging agent used in positron emission tomography scans for prostate cancer detection. This firm fixed-price contract carries no set-aside designation and extends through March 24, 2026, with performance occurring at the...
- Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., was awarded a $1.9M delivery order by Veterans Integrated Service Network 17 on January 1, 2025, with a completion deadline of December 31, 2025, for an increase in quantity of PYLARIFY (piflufolastat F-18). This award represents a firm fixed-price delivery order issued without set-aside designation under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) master contract. Performance will...
- Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., received a delivery order from Veterans Integrated Service Network (VISN) 7 on November 1, 2023, for the supply of 80 units of PYLARIFY (piflufolastat F-18), a radioactive diagnostic imaging agent used in positron emission tomography scans for prostate cancer detection. This firm fixed-price delivery order, valued at $2.85M with an ultimate completion date of October 31, 2028, carries no set-aside...